FGFR2 and gastric cancer: First, this case clearly shows that patients with GC and FGFR2 amplification may durably respond to FGFR-inhibitor therapy, despite the lack of observed additional benefits provided by AZD4547 compared to those by AZD4547 (+) paclitaxel in a recent randomized phase II trial [9].